Form 4: Inhibikase Therapeutics Director Receives Significant Stock Option Grant

Inhibikase Therapeutics, Inc. Director Arvind Kush was granted 108,176 stock options with an exercise price of $1.95, vesting by June 30, 2026.

Summary

• Director Arvind Kush of Inhibikase Therapeutics, Inc. (IKT) was granted 108,176 stock options.
• The stock options have an exercise price of $1.95 per share.
• The transaction date for the option grant was June 30, 2025.
• The options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders, subject to the director's continued service.
• The expiration date for these stock options is June 30, 2032.
• Following this transaction, Arvind Kush beneficially owns 108,176 derivative securities (stock options) directly.
• A Limited Power of Attorney was executed on July 2, 2025, appointing David McIntyre and Mark Iwicki as attorneys-in-fact to prepare and file SEC reports on behalf of Arvind Kush.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step in aligning management incentives with shareholder value, though it does not represent an immediate cash transaction or direct financial gain for the company.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value of Inhibikase Therapeutics.
• The options were granted at a price of $0, indicating they are a form of equity compensation rather than a purchase, which is beneficial for the recipient.

Negatives

• The value of the options is contingent on the company's stock price exceeding the exercise price of $1.95.
• The options are subject to vesting conditions, requiring continued service until June 30, 2026, or the day prior to the next annual meeting of stockholders.

Risks

• The value of the stock options is subject to market fluctuations and the future performance of Inhibikase Therapeutics' common stock.
• The options will only have intrinsic value if the company's stock price rises above the $1.95 exercise price.
• Vesting is conditional on the director's continued service, meaning the options could be forfeited if service ceases before the vesting date.

Future Outlook

The grant of stock options to Director Arvind Kush aligns future incentives with the company's long-term performance, as the options are set to vest by June 30, 2026, contingent on continued service.

Management Comments

• The grant of stock options to Director Arvind Kush is a standard practice designed to align the director's long-term interests with those of the company and its shareholders.

Industry Context

The grant of stock options to directors is a common form of equity compensation in the biotechnology and pharmaceutical industries, used to attract and retain talent while aligning leadership incentives with shareholder value creation.

Comparison to Industry Standards

• The grant of stock options is a standard component of director compensation across the biotechnology and pharmaceutical industries, aiming to align the interests of directors with long-term shareholder value.
• Specific comparable companies or projects are not detailed within this filing, but this compensation structure is widely adopted by peers in the sector.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aims to align the director's interests with long-term shareholder value.
• Director (Arvind Kush): Receives a significant equity incentive, contingent on continued service and company performance.

Next Steps

• The stock options will vest on the earlier of June 30, 2026, or the day prior to the next annual meeting of stockholders, subject to continued service.

Key Dates

Recommendation

Keywords

Inhibikase Therapeutics, IKT, Stock Option, Director Compensation, Insider Transaction, Equity Grant, Form 4, Arvind Kush, Derivative Securities